Human Genome reiterated at market outperform

JMP Securities analyst Charles C. Duncan reiterated Human Genome Sciences, Inc. at market outperform and a $15 price target following the company's financial results a non-event. Human Genome had better-than-expected revenues and in line net loss per share compared to JMP's estimates. The analyst raised his 2006 revenue estimate to $25 million from $23 million, and increased its 2006 net loss to $1.79 per share, from $1.78 per share. Shares of the Rockville, Md., biopharmaceutical company were down $0.22 or 1.90%, at $11.37 on volume of 2,785,573 shares versus the three-month running average of 3,596,260 shares. (Nasdaq: HGSI)

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.